{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T11:06:47Z","timestamp":1789816007092,"version":"4.0.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"9-10","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.drudis.2009.02.002","type":"journal-article","created":{"date-parts":[[2009,2,17]],"date-time":"2009-02-17T20:48:45Z","timestamp":1234903725000},"page":"500-508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":228,"title":["Organometallic compounds in oncology: implications of novel organotins as antitumor agents"],"prefix":"10.1016","volume":"14","author":[{"given":"Angela","family":"Alama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Tasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Sparatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2009.02.002_bib1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/222385a0","article-title":"Platinum compounds: a new class of potent antitumour agents","volume":"222","author":"Rosenberg","year":"1969","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2009.02.002_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jlac.18440510102","article-title":"Ueber die Einvirkung des Ammonia auf Platin chlorur","volume":"51","author":"Peyrone","year":"1844","journal-title":"Ann. Chem. Pharm."},{"key":"10.1016\/j.drudis.2009.02.002_bib3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1021\/cr020010d","article-title":"Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance","volume":"103","author":"Fuertes","year":"2003","journal-title":"Chem. Rev."},{"key":"10.1016\/j.drudis.2009.02.002_bib4","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1021\/cr068207j","article-title":"Direct cellular responses to platinum-induced DNA damage","volume":"107","author":"Jung","year":"2007","journal-title":"Chem. Rev."},{"key":"10.1016\/j.drudis.2009.02.002_bib5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev."},{"key":"10.1016\/j.drudis.2009.02.002_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1039\/B712656P","article-title":"Antitumor metal compounds: more than theme and variations","author":"Yakupec","year":"2008","journal-title":"Dalton Trans."},{"key":"10.1016\/j.drudis.2009.02.002_bib7","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1021\/cr040704h","article-title":"Interactions of antitumor metallo drugs with serum proteins: advances in characterization using modern analytical methodology","volume":"106","author":"Timerbaev","year":"2006","journal-title":"Chem. Rev."},{"key":"10.1016\/j.drudis.2009.02.002_bib8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s002800000261","article-title":"Antitumoral activity of a sulfur-containing platinum complex with an acidic pH optimum","volume":"47","author":"Amtmann","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.drudis.2009.02.002_bib9","first-page":"2063","article-title":"cis-Amminedichloro(2.methylpyridine)platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology and pharmacokinetics in mice","volume":"3","author":"Raynaud","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2009.02.002_bib10","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1517\/13543784.16.7.1009","article-title":"Broadening the clinical use of platinum drug-based chemotherapy with new analogues, satraplatin and picoplatin","volume":"16","author":"Kelland","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2009.02.002_bib11","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-07-2176","article-title":"Current status and future prospects for satraplatin, an oral platinum analogue","volume":"14","author":"Choy","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2009.02.002_bib12","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/ja0432618","article-title":"Rational design of platinum(IV) compound to overcome glutathione-S-transferase mediated drug resistance","volume":"127","author":"Ang","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drudis.2009.02.002_bib13","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1021\/ja036105u","article-title":"Long range 1,4 and 1,6-interstrand cross-links formed by a trinuclear platinum complex. Minor groove preassociation affects kinetics and mechanism of cross-link formation as well as adduct structure","volume":"126","author":"Hegmans","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drudis.2009.02.002_bib14","doi-asserted-by":"crossref","first-page":"16092","DOI":"10.1021\/ja062851y","article-title":"A third mode of DNA binding: phosphate clamps by a polynuclear platinum complex","volume":"128","author":"Komeda","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drudis.2009.02.002_bib15","doi-asserted-by":"crossref","first-page":"20743","DOI":"10.1073\/pnas.0707742105","article-title":"A potent cytotoxic photoactivated platinum complex","volume":"104","author":"Mackay","year":"2007","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"10.1016\/j.drudis.2009.02.002_bib16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF02175963","article-title":"Zur experimentellen Therapie der Tumoren. I. Die Wirksamkeit einiger metallorganischen Blei- und Zinnverbindungen","volume":"110","author":"Collier","year":"1929","journal-title":"Z. Hygiene Infektionkr."},{"key":"10.1016\/j.drudis.2009.02.002_bib17","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2174\/092986706776360941","article-title":"Ruthenium complexes as anticancer agents","volume":"13","author":"Kostova","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.drudis.2009.02.002_bib18","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jinorgbio.2006.02.013","article-title":"From bench to bedside-preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachloro bis(1H-indazole)ruthenate(III)] (KP1019 or FFC144)","volume":"100","author":"Hartinger","year":"2006","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.drudis.2009.02.002_bib19","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1158\/1078-0432.CCR-03-0746","article-title":"A phase I and pharmacological study with imidazolium-trans-DMSO-imidazoletetrachlororuthenate, a novel ruthenium anticancer agent","volume":"10","author":"Rademaker-Lakhai","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2009.02.002_bib20","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/BF00390468","article-title":"Ferricenium complexes: a new type of water-soluble antitumor agent","volume":"108","author":"K\u00f6pf-Maier","year":"1984","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.drudis.2009.02.002_bib21","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1021\/jm050251o","article-title":"Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro","volume":"48","author":"Vessi\u00e8res","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2009.02.002_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/anie.200502925","article-title":"Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates","volume":"45","author":"Hillard","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.drudis.2009.02.002_bib23","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1021\/cr960438a","article-title":"Cleavage of nucleic acid by bleomycin","volume":"98","author":"Burger","year":"1998","journal-title":"Chem. Rev."},{"key":"10.1016\/j.drudis.2009.02.002_bib24","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1021\/jm049326z","article-title":"Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: studies on the mode of drug action","volume":"48","author":"Ott","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2009.02.002_bib25","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2174\/138955706777698660","article-title":"Cyclooxygenases in cancer: chemoprevention and sensitization to conventional therapies","volume":"6","author":"Jean","year":"2006","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.drudis.2009.02.002_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/BF00193472","article-title":"Complex of metals other than platinum as antitumor agents","volume":"47","author":"K\u00f6pf-Maier","year":"1994","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2009.02.002_bib27","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2174\/1568026043387449","article-title":"Gallium in cancer treatment","volume":"4","author":"Jakupec","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.drudis.2009.02.002_bib28","doi-asserted-by":"crossref","first-page":"590","DOI":"10.5414\/CPP43590","article-title":"Early results from a phase I study on orally administered tris-(8-quinolinolato)gallium(III) (FTC11, KP46) in patients with solid tumors","volume":"4","author":"Hofheinz","year":"2005","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2009.02.002_bib29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/13543784.13.5.531","article-title":"Gallium nitrate for the treatment of non-Hodgkin lymphoma","volume":"13","author":"Chitambar","year":"2004","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2009.02.002_bib30","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1021\/cr9804285","article-title":"Metal complexes as enzyme inhibitors","volume":"99","author":"Louie","year":"1999","journal-title":"Chem. Rev."},{"key":"10.1016\/j.drudis.2009.02.002_bib31","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.ccr.2007.04.006","article-title":"Targetin the mitochondrial cell death pathway with gold compounds","volume":"251","author":"Barnard","year":"2007","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.drudis.2009.02.002_bib32","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0300-483X(02)00464-X","article-title":"Role of mitochondria in toxic cell death","volume":"181\u2013182","author":"Robertson","year":"2002","journal-title":"Toxicology"},{"key":"10.1016\/j.drudis.2009.02.002_bib33","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1021\/cr980431o","article-title":"Gold-based therapeutic agents","volume":"99","author":"Shaw","year":"1999","journal-title":"Chem. Rev."},{"key":"10.1016\/j.drudis.2009.02.002_bib34","series-title":"Frontiers in Bioinorganic Chemistry","first-page":"376","article-title":"Gold drugs","author":"Berners Price","year":"1986"},{"key":"10.1016\/j.drudis.2009.02.002_bib35","first-page":"5486","article-title":"In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride","volume":"46","author":"Berners Price","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2009.02.002_bib36","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.coph.2007.04.003","article-title":"Thioredoxin signalling as a target for cancer therapy","volume":"7","author":"Powis","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.drudis.2009.02.002_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/med.10051","article-title":"The thioredoxin system- From science to clinic","volume":"24","author":"Gromer","year":"2004","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.drudis.2009.02.002_bib38","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/anie.200502756","article-title":"Undressing of phosphinegold(I) complexes as irreversible inhibitors of human disulfide reductase","volume":"45","author":"Urig","year":"2006","journal-title":"Angew. Chem., Int. Ed."},{"key":"10.1016\/j.drudis.2009.02.002_bib39","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00249-005-0472-1","article-title":"A predictive model for the selective accumulation of chemicals in tumor cells","volume":"34","author":"Trapp","year":"2005","journal-title":"Eur. Biophys. J."},{"key":"10.1016\/j.drudis.2009.02.002_bib40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/00001813-199808000-00005","article-title":"Synthesis and biological activity of gold and tin compounds in ovarian cancer cells","volume":"9","author":"Cagnoli","year":"1998","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.drudis.2009.02.002_bib41","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jinorgbio.2007.11.003","article-title":"Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action","volume":"102","author":"Casini","year":"2008","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.drudis.2009.02.002_bib42","first-page":"255","article-title":"The chemotherapeutic properties of tin compounds","volume":"12","author":"Crowe","year":"1987","journal-title":"Drugs Fut."},{"key":"10.1016\/j.drudis.2009.02.002_bib43","series-title":"Tin-Based Antitumor Drugs","year":"1990"},{"key":"10.1016\/j.drudis.2009.02.002_bib44","series-title":"Metallotherapeutic Drugs and Metal-Based Diagnostic Agents. The Use of Metals in Medicine","first-page":"421","article-title":"Tin compounds and their therapeutic potential","author":"Gielen","year":"2005"},{"key":"10.1016\/j.drudis.2009.02.002_bib45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ccr.2007.12.026","article-title":"Antiproliferative and anti-tumor activity of organotin compounds","volume":"253","author":"Hadjikakou","year":"2008","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.drudis.2009.02.002_bib46","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1039\/b106665j","article-title":"The interaction of organotin(IV) acceptors with 1,4-bis(5-hydroxy-1-phenyl-3-methyl-1H-pyrazol-4-yl)butane-1,4-dione","author":"Pettinari","year":"2002","journal-title":"Dalton Trans."},{"key":"10.1016\/j.drudis.2009.02.002_bib47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0141-1136(85)90061-3","article-title":"Metabolism of tributyltin oxide by crabs, oyster and fish","volume":"17","author":"Lee","year":"1985","journal-title":"Marine Envir. Res."},{"key":"10.1016\/j.drudis.2009.02.002_bib48","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0003-9861(90)90610-B","article-title":"Tributyltin stimulates apoptosis in rat thymocytes","volume":"283","author":"Aw","year":"1990","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.drudis.2009.02.002_bib49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1006\/taap.1996.0224","article-title":"Triethyltin interferes with Ca2+ signalling and potentiates norepinephrine release in PC12 cells","volume":"140","author":"Viviani","year":"1996","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.drudis.2009.02.002_bib50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/tox.20170","article-title":"Tributyltin induces DNA damage as well as oxidative damage in rats","volume":"21","author":"Liu","year":"2006","journal-title":"Environ. Toxicol."},{"key":"10.1016\/j.drudis.2009.02.002_bib51","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.toxlet.2004.10.009","article-title":"Some organotin compounds enhance histone acetyltransferase activity","volume":"155","author":"Osada","year":"2005","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.drudis.2009.02.002_bib52","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2131\/jts.33.269","article-title":"Endocrine disruption by organotin compounds; organotins function as a powerful agonist for nuclear receptors rather than an aromatase inhibitor","volume":"33","author":"Nakanishi","year":"2008","journal-title":"J. Toxicol Sci."},{"key":"10.1016\/j.drudis.2009.02.002_bib53","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0162-0134(99)00161-0","article-title":"Synthesis, characterization and in vitro antitumor activity of di- and triorganotin derivatives of polyoxa- and biologically relevant carboxylic acids","volume":"79","author":"Gielen","year":"2000","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.drudis.2009.02.002_bib54","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10904-007-9158-8","article-title":"Synthesis, structural characterization and ability to inhibit cancer growth of organotin poly(ethyleneglycols)","volume":"17","author":"Barot","year":"2007","journal-title":"J. Inorg. Organomet. Polym."},{"key":"10.1016\/j.drudis.2009.02.002_bib55","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10904-007-9184-6","article-title":"Synthesis and initial cell lines results of organotin polyethers containing diethylstilbestrol","volume":"18","author":"Carraher","year":"2008","journal-title":"J. Inorg. Organomet. polym"},{"key":"10.1016\/j.drudis.2009.02.002_bib56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1248\/cpb.54.54","article-title":"Synthesis, characterization and in vitro cytotoxicity of pentacoordinated tin(IV) complexes derived from aminoalcohols","volume":"54","author":"Gomez","year":"2006","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.drudis.2009.02.002_bib57","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s11172-007-0115-z","article-title":"Biological studies of organotin(IV) complexes with 2-mercaptopyrimidine","volume":"56","author":"Xanthopoulou","year":"2007","journal-title":"Russ. Chem. Bull., Int. Ed."},{"key":"10.1016\/j.drudis.2009.02.002_bib58","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jinorgbio.2007.12.027","article-title":"Synthesis, structural characterization and biological study of new organotin(IV), silver(I) and antimony(III) complexes with thioamides","volume":"102","author":"Hadjikakou","year":"2008","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.drudis.2009.02.002_bib59","first-page":"977","article-title":"Cytotoxicity in vitro and preliminary anti-tumor activity in vivo of a novel organotin compound","volume":"20","author":"Barbieri","year":"2000","journal-title":"Anticancer Res."},{"key":"10.1016\/j.drudis.2009.02.002_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0009-2797(00)00249-0","article-title":"Antiproliferative activity and interactions with cell-cycle related proteins of the organotin compound triethyltin(IV) lupinylsulfide hydrochloride","volume":"134","author":"Barbieri","year":"2001","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.drudis.2009.02.002_bib61","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1020630214549","article-title":"Chemosensitivity of glioblastoma cells during treatment with the organotin compound triethyltin(IV) lupinylsulfide hydrochloride","volume":"60","author":"Barbieri","year":"2002","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.drudis.2009.02.002_bib62","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00001813-200207000-00006","article-title":"Antitumor activity of a new orally active organotin compound: a preliminary study in murine tumor models","volume":"13","author":"Barbieri","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.drudis.2009.02.002_bib63","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s10637-008-9148-x","article-title":"In vitro cytotoxic activity of tri-n-butyltin(IV)lupinylsulfide hydrogen fumarate (IST-FS 35) and preliminary antitumor activity in vivo","volume":"27","author":"Alama","year":"2009","journal-title":"Invest. New Drugs"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644609000415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644609000415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:04:49Z","timestamp":1761221089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644609000415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":63,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S1359644609000415"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2009.02.002","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Organometallic compounds in oncology: implications of novel organotins as antitumor agents","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2009.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}